ArticleBMC medical imaging2026
Comparing multi-b-value diffusion models and ROI delineation strategies for prediction of p53 abnormality and microsatellite instability in endometrial cancer.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMulti-b-value diffusion-weighted MRI holds potential for noninvasively predicting p53 abnormality and microsatellite instability (MSI) in endometrial cancer (EC), but the optimal diffusion model and region of interest (ROI) strategy remain undetermined. This study aims to identify the optimal diffusion model-ROI strategy combination for predicting p53 abnormality and MSI status by comparing diffusion MRI-derived parameters from three ROI approaches.
methodsThis retrospective study included patients with EC who underwent preoperative multi-b-value diffusion MRI between December 2020 and June 2025. Two radiologists independently quantified apparent diffusion coefficient (ADC), intravoxel incoherent motion (IVIM), and diffusion kurtosis imaging (DKI) parameters using three ROI strategies (single-slice ROI [ssROI], three-slice ROI [tsROI], and whole-tumor volume ROI [wtROI]. Multivariable logistic regression identified parameters associated with p53 abnormality and MSI. Diagnostic performance was assessed using the receiver operating characteristic curve and compared with the DeLong test. Additionally, the reproducibility of the parameters was evaluated.
resultsAmong 143 enrolled patients (mean age, 57.73years ± 10.01[SD]), 136 were assessed for p53 status (37 abnormal) and 109 for mismatch repair status (17 MSI). All parameters showed good-to-excellent reproducibility. Elevated D* and lower MD in ssROI, lower D in tsROI, and decreased MD in wtROI were associated with p53 abnormality. Lower ADC across all ROIs was associated with MSI. For predicting p53 abnormality, ssROI-MD yielded the highest AUC of 0.711 (95% CI: 0.627, 0.785), which showed similar performance to other parameter-ROI combinations. For predicting MSI, tsROI-ADC (AUC,0.755 [95%CI:0.646, 0.844]) and wtROI-ADC (AUC,0.758 [95%CI:0.649, 0.846]) significantly outperformed ssROI-ADC (AUC,0.700 [95%CI:0.587, 0.797]; p = 0.006 and 0.025, respectively), with wtROI-ADC showing higher sensitivity (90.9%).
conclusionsMD from a single-slice ROI is optimal for the identification of p53 abnormality, combining diagnostic performance with operational simplicity and high reproducibility. For MSI prediction, ADC from a whole-tumor ROI is preferred due to its superior sensitivity and excellent reproducibility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.